Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Refractory asthma - beyond step 5, the role of new and emerging adjuvant therapies

Kane, Binita, Fowler, Stephen J, Niven, Rob · 2015 · Chronic Respiratory Disease

Abstract

A small percentage of asthmatics have 'severe refractory asthma', where there is suboptimal response to currently available therapies. A number of novel therapies targeting key biological targets are becoming available. Asthma is a heterogeneous disease, and systematic evaluation of patients is important to target therapies to the underlying inflammatory subtype and clinical features. This review article outlines new and emerging treatments for severe asthma, including monoclonal antibodies targeting eosinophilic disease, anti-neutrophil strategies, novel bronchodilators and bronchial thermoplasty. We highlight the importance of individualized investigation, treatment and management of severe asthmatics.

Overview

Integrity signals

Registry

Crossref · 10.1177/1479972314562210

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 65 references

Research works printed but not linked: 11

  1. Carter PM, 1997, J Investig Allergol Clin Immunol, 7, 566
  2. Domingo RC, 1999, Rev Clin Esp, 199, 142
  3. Agbetile J, 2013, J Allergy Clin Immunol, 10
  4. Richeldi L, 2005, Cochrane Database Syst Rev, CD002997
  5. Wilkinson M, 2014, Cochrane Database Syst Rev, 5, CD001289
  6. Gauvreau GM, 2011, Respir Res, 140, 12
  7. 10.1016/S0140-6736(02)11679-5 · DOI · Paper page
  8. Castro M, 2014, Am J Respir Crit Care Med, 101, A3699
  9. Singh D, 2010, BMC Pulm Med, 3, 10
  10. Novelli F, 2013, Monaldi Arch Chest Dis, 79, 109
  11. Befekadu E, 2014, J Asthma Allergy, 7, 11

Cited by

See all 15

Metadata

Authors
Kane, B., Fowler, S. J., & Niven, R.
Affiliations
  • Manchester Academic Health Science Centre (GB)
  • Lancashire Teaching Hospitals NHS Foundation Trust (GB)
  • Manchester Academic Health Science Centre, University Hospital of South Manchester, University of Manchester, Southmoor Road, Manchester, UK
Corresponding author
Kane, Binita
Venue
Chronic Respiratory Disease
Published
2014-12-09
Volume
12
Issue
1
Pages
69-77
ISSN
  • 1479-9723 (ISSN-L)
  • 1479-9731
OpenAlex
W2081294470
Cited by
15
References
65
Citations by year
2024: 1 · 2023: 2 · 2022: 1 · 2019: 2 · 2018: 1 · 2017: 3 · 2016: 3 · 2015: 2
FWCI
1.77
Type
journal article
Language
en
Open access
closed
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Chronic Respiratory Disease (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (submittedVersion)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Occupational exposure and asthma
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
Keywords
refractory asthma, severe asthma, adjuvant therapy, monoclonal antibodies, eosinophilic asthma, bronchial thermoplasty, asthma phenotypes, personalized asthma management
MeSH terms
Omalizumab, Antibodies, Anti-Idiotypic, Antibodies, Monoclonal, Antifungal Agents, Asthma, Bronchi, Bronchodilator Agents, Bronchoscopy, Fungi, Humans, Hypersensitivity, Hyperthermia, Induced, Tumor Necrosis Factor-alpha, Interleukin-4, Treatment Failure, Itraconazole, Anti-Asthmatic Agents, Macrolides, Phosphodiesterase 4 Inhibitors, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Refractory asthma - beyond step 5, the role of new and emerging adjuvant therapies. https://app.cochat.ai/papers/10.1177/1479972314562210
The paper
Kane, B., Fowler, S. J., & Niven, R. (2015). Refractory asthma - beyond step 5, the role of new and emerging adjuvant therapies. Chronic Respiratory Disease. https://doi.org/10.1177/1479972314562210

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.